The UCLA Lung Cancer Program is comprised of a multidisciplinary team of experts who are dedicated to the prevention, detection, treatment, and research of lung cancer.
 
Schedule an Appointment
Lung Cancer Home
About Us
Our Expert Team
Our Services
Thoracic Surgery
First Visit for Patients
Patient Education
Clinical Trials
For Referring Physicians
Lung Screening Clinic
Insurance Questions
Map-Directions-Parking
Contact Us
Giving / Donations
Webcasts
Resources
Site Map



Schedule an Appointment

Clinical Trials


Clinical Trials - Lung Cancer Program at UCLA - Los Angeles, California



Study Name  

Drug name or type

Disease

PI

Contact

AstraZeneca D5164C00001 (ADAURA) NSCLC

osimertinib (3rd generation EGFR TKI) versus placebo

EGFR mutation positive, stage IB-IIIA NSCLC, following complete tumor resection

Goldman

Jaime Hunt (310) 794-3894

Lilly 14T-MC-JVCY NSCLC

ramucirumab (anti-VEGFR2) versus placebo

treatment naïve, EGFR mutation positive, NSCLC

Garon

Jaime Hunt (310) 794-3896

MedImmune D4190C00006 NSCLC

MEDI4736 (anti-PD-L1) + tremelimumab (anti-CTLA-4)

previously treated, NSCLC

Garon

Jaime Hunt (310) 794-3897

Plexxikon PLX108-14 Solid Tumors

PLX3397 (CSF1R inhibitor) + pembrolizumab (immunotherapy)

Solid Tumors

Hu-Lieskovan

Jaime Hunt (310) 794-3898

MacroGenics CP-MGA271-02 Solid Tumors

MGA271 + Ipilimumab (anti-CTLA-4)

Chimielowski

Jaime Hunt (310) 794-3899

Abound 70+

abraxane + carboplatin

elderly subjects + advanced NSCLC

Goldman

Jaime Hunt (310) 794-3900

Amgen 20070782

Chemotherapy

Anemic NSCLC

Glaspy

Jaime Hunt (310) 794-3901

Celgene ABI-007-ST-001 Solid Tumors

Azacitidine + chemotherapy

Solid Tumors

Wainberg

Jaime Hunt (310) 794-3902

Checkmate 153

Nivolumab (anti-PD-1)

previously treated, adanced or metastatic NSCLC

Garon

Jaime Hunt (310) 794-3903

EMD Serono EMR100070-001 Solid Tumor

Avelumab (anti-PD-L1)

Solid Tumors

Wong

Jaime Hunt (310) 794-3904

Lilly 13Y-MC-JPBJ NSCLC

LY2835219 + anti cancer drug (pemetrexed, gemcitabine, ramucirumab, LY3023414)

Stage IV NSCLC 

Goldman

Jaime Hunt (310) 794-3905

Lilly I3Y-MC-JPBK

Abemaciclib (CDK 4/6 Dual Inhibitor) + SOC vs. Erlotinib + SOC

Previously treated KRASm metastatic NSCLC

Goldman

Jaime Hunt (310) 794-3906

Pfizer B1641003 Solid Tumors

Pf-05082566 (4-1bb agonist) + pembrolizumab (anti-PD-L1)

Previously treated advanced/metastatic solid tumors

Hu-Lieskovan

Jaime Hunt (310) 794-3907

Pfizer B2151002 Solid Tumors

PF-05212384 (PI3K/MTOR inhibitor) + docetaxel, cisplatin, or dacomitinib

NSCLC

Wainberg

Jaime Hunt (310) 794-3908

Roche GO29322 Solid Tumors

MPDL3280A (anti-PD-L1) + Ipilimumab (anti-CTLA-4) vs MPDL3280A + Interferon-alpha

Advanced or metastatic solid tumors

Wong

Jaime Hunt (310) 794-3909

Pfizer B1641001 Advanced Cancer/NHL

PF-05082566 (anti 4-1BB)

relapsed or refractory NSCLC

Hu-Lieskovan

Jaime Hunt (310) 794-3911

BI 1302.5

BI 695502 (angiogenesis inhibitor) plus chemotherapy versus Avastin (angiogenesis inhibitor) plus chemotherapy

advanced, nonsquamous, NSCLC

Garon

Jaime Hunt (310) 794-3912

Checkmate 370

Nivolumab (immunotherapy)

treatment naïve or previously treated with chemotherapy, advanced NSCLC

Glaspy

Jaime Hunt (310) 794-3913

CINC280A2201

INC280 (cMET Inhibitor)

NSCLC who have received one or two prior lines of systemic therapy

Garon

Jaime Hunt (310) 794-3914